AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate failed a key survival endpoint in a late-phase breast ...

The former head of vaccine R&D at GSK has pulled together $100 million for a London-based biotech working on respiratory ...

As an­ti­body–drug con­ju­gates (AD­Cs) and im­mune check­point in­hibitors con­tin­ue to grab a lot of at­ten­tion as trans­for­ma­tive can­cer ther­a­pies, they would ap­pear to leave lit­tle room ...

The US Court of Appeals for the Fifth Circuit is reviving PhRMA's legal attack on Medicare drug price negotiations. On Friday ...

Another biotech startup revealed plans Friday evening for an initial public offering, making it the sixth startup to list new ...

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every ...

This week, a letter surfaced in which Eli Lilly asked for a patient to release medical information so it could contact her ...

A startup in Brazil that lets people easily buy medicine online by combining a consumer-friendly experience with prescription ...

The US' Health Resources and Services Administration threatened Johnson & Johnson with fines for unilaterally reshaping the ...

Yuhan and Johnson & Johnson Innovative Medicine (JJIM), formerly known as Janssen, ended a research project after securing ...

The Federal Trade Commission said that it is suing the three major US pharmacy benefit managers over their role in the ...

Despite largely exiting oncology, Sanofi continues to reap the benefit of its multiple myeloma treatment Sarclisa. The FDA on ...